Isabella Ciccone, MPH

A post hoc analysis of the phase 3 EPIDYS trial presented at CNS 2025 revealed that givinostat delayed disease progression in 2 distinct age groups of patients with Duchenne muscular dystrophy.

The neurologist at University of British Columbia discussed how abnormal brain plasticity influences Parkinson progression and highlighted the importance of integrating basic science with clinical care.

Results from the extension phase of the IB1001-203 study, presented as a late-breaker at MDS 2025, suggest N-acetyl-L-leucine prevented worsening of disease progression in patients with ataxia-telangiectasia.

In the MOXIe open-label extension study presented at MDS 2025, omaveloxolone treatment was associated with no significant disease progression in bulbar function or upper limb coordination.

The neurologist at University of British Columbia discussed how breakdowns in brain organization and compensatory mechanisms may influence progression in Parkinson disease. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Final results from a phase 3 extension study presented at ECTRIMS 2025 demonstrated long-term efficacy and safety of ravulizumab-cwvz in patients with neuromyelitis optica spectrum disorder.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

At ECTRIMS 2025, a staff neurologist at Cleveland Clinic discussed findings from an observational study on long-term safety risks of ocrelizumab in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

At ECTRIMS 2025, the postdoctoral research fellow at the University of Siena in Italy talked about how machine learning could classify multiple sclerosis into biologically distinct subtypes. [WATCH TIME: 5 minutes]

In a phase 3 trial presented at ECTRIMS 2025, ocrelizumab demonstrated noninferior relapse control compared with fingolimod in pediatric patients with relapsing-remitting multiple sclerosis.

Primary results presented at ECTRIMS 2025 suggest that body-weight–adjusted high-dose of ocrelizumab did not further slow disease progression in patients with primary progressive multiple sclerosis.

A phase 2 study presented at ECTRIMS 2025 showed that autologous adipose-derived mesenchymal stem cell therapy was safe and effective in patients with relapsing-remitting multiple sclerosis.

At ECTRIMS 2025, the associate professor of neurology at Yale School of Medicine talked about the 2024 diagnostic criteria, the preclinical phase of the disease, and progressive MS. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The executive director of The Sumaira Foundation (TSF) talked about TSF's research update and award ceremony held during ECTRIMS 2025. [WATCH TIME: 5 minutes]

A global panel of experts revised NMOSD diagnostic criteria and updated disease classifications, distinguishing aquaporin-4 antibody–positive disease from related conditions such as MOGAD.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.

At ECTRIMS 2025, the professor of neurology at the University of Basel talked about the decades of progress in MS therapeutics and highlighted the need for comprehensive, early assessments for patients. [WATCH TIME: 4 minutes]

At ECTRIMS 2025, experts discussed using AI-powered unstructured data processing to enhance understanding of drug efficacy, safety, and patient outcomes in multiple sclerosis. [WATCH TIME: 3 minutes]

In a head-to-head phase 3 trial presented at ECTRIMS 2025, rituximab was noninferior to cladribine in preventing new or enlarging MRI lesions in relapsing-remitting multiple sclerosis.

In a late-breaking presentation at ECTRIMS 2025, findings showed that annual administration of rituximab was noninferior in efficacy to the 6-monthly treatment for relapsing-remitting multiple sclerosis.

At ECTRIMS 2025, the professor of neurology at Karolinska Institutet provided clinical insights on results from the phase 3 RIDOSE-MS trial of yearly rituximab in relapsing-remitting multiple sclerosis. [WATCH TIME: 5 minutes]

At ECTRIMS 2025, the interim chief executive officer at the Consortium of Multiple Sclerosis Centers discussed recent progress in multiple sclerosis for treatment and diagnosis. [WATCH TIME: 5 minutes]

Late-breaking results of the ORATORIO-HAND study presented at ECTRIMS 2025 suggest that ocrelizumab slowed both overall disability progression and loss of hand function in patients with primary progressive multiple sclerosis.

A new trial evaluates PIPE-307, a drug targeting M1 receptors, aiming to promote remyelination in relapsing-remitting multiple sclerosis patients.

Scholar Rock navigates FDA hurdles for apitegromab, a promising treatment for spinal muscular atrophy, aiming for resubmission after addressing manufacturing concerns.

At the 2025 STARS Research & Education Conference, Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted risk factors and care interventions for stuttering in children.

Here's some of what is coming soon to NeurologyLive® this week.

Speech-language pathologist Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted the role of interdisciplinary collaboration in the management of stuttering.